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ABSTRACT: The aryloxy triester phosphoramidate prodrug approach has been used with success in drug discovery. Herein, we 
describe the first application of this prodrug technology to the monophosphate derivative of the phosphoantigen HMBPP and one of 
its analogues. Some of these prodrugs exhibited specific and potent activation of Vγ9/Vδ2 T-cells, which were then able to lyse 
bladder cancer cells in vitro. This work highlights the promise of this prodrug technology in the discovery of novel immunotherapeu-
tics. 
INTRODUCTION 
Present since birth,1 Vγ9/Vδ2 T-cells represent the dominant 
subtype of human γδ T-cells in adult peripheral blood.2 They 
expand in response to various infections, including tuberculo-
sis, leprosy, typhoid, malaria, and toxoplasmosis, and studies in 
primate models have suggested a role in immunity to Mycobac-
terium tuberculosis.3 Interestingly, they also exhibited an abil-
ity to target and lyse a diverse range of cancer cells in vitro.2 
Such properties have made the Vγ9/Vδ2 subset a major focus 
in the therapeutic exploitation of γδ T-cells.4 
Interestingly, Vγ9/Vδ2 T-cells have been shown to be acti-
vated by small molecule phosphoantigens (PAg) such as (E)-4-
hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) and 
isopentenyl pyrophosphate (IPP) (Figure 1).5, 6 Beyond these 
natural ligands, two synthetic molecules, Risedronate and 
Zoledronate, activate Vγ9/Vδ2 T-cells through accumulation of 
IPP and are currently used in the clinic to treat osteoporosis and 
some types of cancer (Figure 1).7-9 
 
Figure 1. Chemical structures of natural phosphoantigens 
HMBPP and IPP as well as synthetic molecules Risedronate 
and Zoledronate, which activate Vγ9/Vδ2 T-cells.  
 
The mechanism by which these small molecule phosphoanti-
gens activate Vγ9/Vδ2 T-cells is understood to be mediated by 
the type-1 transmembrane protein butyrophilin 3A1.10, 11 Alt-
hough conflicting reports exist as to whether PAgs bind to the 
extracellular or intracellular domains of this transmembrane 
protein, there is an increasing body of evidence that supports 
the notion that these PAgs bind the intracellular B30.2 domain 
of butyrophilin 3A1.10, 12-15  
Encouraged by Vγ9/Vδ2 T-cells’ ability to mount immune 
responses towards pathogens, lyse tumor cells, as well as their 
amenability to be targeted and modulated by small molecules 
(PAgs and their synthetic mimics), we embarked on the discov-
ery of small molecules that have the potential to activate 
Vγ9/Vδ2 T-cells. Given our interest in the discovery and devel-
opment of phosphorylated molecules and their prodrugs as ther-
apeutics,16-18 we focused our efforts on the natural phosphoanti-
gen HMBPP as it is the most potent activator of Vγ9/Vδ2 T-
cells reported to date (Figure 1).19 HMBPP has a pyrophosphate 
group, which accounts for poor drug-like properties namely 
poor cell membrane permeability, due its charged nature under 
physiological conditions (pH ≤ 7.4) and limited in vivo stabil-
ity. These properties have hindered the development of many 
drugs with unmasked phosphate or pyrophosphate groups. To 
overcome these drawbacks, numerous phosphate prodrug strat-
egies have been developed and used with success in the discov-
ery of mostly nucleotide monophosphates and monophospho-
nates.20-22  
There have been reports in the literature of the application of 
the bis-pivaloyloxymethyl (bisPOM) phosphate prodrug tech-
nology and its derivatives to HMBP and its diphosphonates, 
which resulted in potent phosphoantigens though these were 
less potent than the parent phosphoantigen HMBPP.19, 23-25 Aim-
ing to discover phosphoantigen prodrugs that are as potent as 
HMBPP, we focused our work on the aryloxy triester phospho-
ramidate26 prodrug approach, in which the monophosphate or 
monophosphonate groups are masked by an aryl motif and an 
amino acid ester moiety. This prodrug technology is known to 
be more efficient in delivering monophosphorylated molecules 
 than the bisPOM approach.27 Over the last decade or so, it has 
led to at least ten clinical candidates with two being eventually 
approved for clinical use.28 Notably, this prodrug approach has 
mostly been used on nucleotide monophosphates and mono-
phosphonates. In this work, we applied this powerful phosphate 
prodrug technology to the monophosphate derivative of the 
phosphoantigen HMBPP, (E)-4-hydroxy-3-methylbut-2-enyl 
phosphate (HMBP). The aryloxy triester phosphoramidate pro-
drugs of the phosphoantigen HMBP will be referred to as 
HMBP ProPAgens in this work.  
RESULTS AND DISCUSSION 
The synthesis of HMBP ProPAgens was similar to that re-
ported by Reichenberg et al.29 Briefly, the hydroxyl group of 1-
hydroxypropan-2-one (1) was protected with TBS in the pres-
ence of imidazole (Scheme 1a). The ether product 2 was then 
treated with a Horner-Wadsworth-Emmons reagent, specifi-
cally triethyl phosphonoacetate, to create the double bond with 
E selectivity and yield the ester product 3. This compound, 3, 
was produced in a mixture of E/Z isomers with a 5:1 ratio sim-
ilar to what is reported in the literature.5 The E/Z isomers were 
separated by column chromatography using solvent mixture of 
5 % to 7 % diethyl ether in hexane. The two products were then 
evaluated with 1H and 13C NMR utilizing previous work by 
Hintz et al5 who performed NOSEY experiments to determine 
the identity of each isomer. The desired E-isomer, 3, was sub-
sequently reduced using lithium aluminum hydride in THF to 
afford the key intermediate 4. The coupling of compound 4 to 
phosphorochloridates to afford the desired prodrugs was 
achieved using standard procedures.17, 18 Phosphorochloridates, 
9a-d, bearing methyl, isopropyl, tert-butyl or benzyl esters, 
were synthesized following the procedure reported by Mehellou 
et al17 and as shown in Scheme 1b. These were coupled to 4 in 
the presence of triethylamine or N-methylimidazole (NMI) to 
afford the desired HMBP ProPAgens, 5a-d, in modest yields. 
Notably, NMI was only used in cases when TEA gave very low 
yields. The removal of the TBS protecting group was initially 
pursued using TBAF in THF.30 However, this strategy did not 
work in our hands as the reaction yielded so many products and 
no traces of the desired HMBP ProPAgens were detected by 
mass spectroscopy. As an alternative, we used mild acidic con-
ditions, 0.1 equivalents of 1.25 M HCl in methanol, and this 
achieved the TBS deprotection without degrading the phos-
phate masking moieties to afford the desired HMBP ProPAgens 
6a-d in good yields. 
The unprotected HMBP ProPAgens 6a-d, however, exhibited 
low stability and underwent rapid degradation, which prevented 
their biological testing (purity < 95%). In order to get an insight 
into the metabolism of ProPAgens 6a-d, compound 6d was in-
cubated with the carboxypeptidase cathepsin A in vitro and the 
reaction was monitored with 31P-NMR. The data show that after 
72 h, the major metabolite had a phosphorous peak at ~ 1.95 
ppm (Supporting Figure S1). Mass spectroscopy analysis of 
these samples showed that the degradation product, which had 
a 31P-NMR peak of ~ 1.95 ppm, was the phosphate group 
masked with the aryl motif and the amino acid ester moiety 
(Supporting Figure S2). This indicated that the P-O bond in 
HMBP ProPAgens 6a-d was liable and was cleaved off to re-
lease the unphopshorylated PAg backbone rather than HMBP. 
This may explain literature reports pursuing the phosphonates 
of HMBP where the –O-P- bond was replaced by a –CH2-P- one 
and lack of reports on the native HMBP phosphate prodrugs.19  
Interestingly, HMBP ProPAgens 5a-d, which had the side 
chain hydroxyl group protected with a TBS moiety exhibited 
better stability than compounds 6a-d and hence we were able to 
characterize them fully and obtain a measure of their purity (see 
Supporting Information). Prodrugs 5a-d were then investigated 
for their ability to activate Vγ9/Vδ2 T-cells. For this, peripheral 
blood mononuclear cells (PBMCs) containing Vγ9/Vδ2 T-cells 
derived from healthy donors were incubated with increasing 
concentrations of HMBPP, Zoledronate or HMBP ProPAgens 
5a-d (up to 100 µM) (Figure 2a and b). Peripheral blood γδ T-
cells lack appreciable levels of surface CD69 or CD25 under 
steady state conditions, but T-cell receptor (TCR) stimulation 
upregulates both T-cell activation markers.31 PAg responsive 
Vγ9/Vδ2 T-cells were then distinguished by TCR Vγ9 and Vδ2 
expression and assessed for the upregulation of CD69 and 
CD25.  
As shown in Figures 2c and d, the natural phosphoantigen 
HMBPP showed significant activation of Vγ9/Vδ2 T-cells, 
EC50 = 0.06 nM, comparable to its reported potency.19 Addi-
tionally, Zoledronate showed a moderate activation, EC50 ~ 500 
nM as expected (Figures 2c and d). The four HMBP ProPAgens 
5a-d exhibited potent Vγ9/Vδ2 T-cell activation with 5b being 
the most potent, EC50 = 0.45 nM, followed by 5a, EC50 = 1.38 
nM. Such potency makes HMBP ProPAgen 5b 1,081-times 
more active than the clinically used agent Zoledronate. The 
other two HMBP ProPAgens also exhibited low nanomolar ac-
tivation of Vγ9/Vδ2 T-cells, 10.62 nM for 5c and 8.92 nM for 
5d (Figures 2c and d). Impressively, CD8+ ab T-cells, which 
are activated by peptides, showed no reactivity towards HMBP 
ProPAgens exemplifying their specificity towards Vγ9/Vδ2 T-
cells (Figure 2e). Notably, the unphopshorylated backbone 
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Scheme 1. A. Synthesis of HMBP ProPAgens. Reagents and con-
ditions: (a) TBSCl, imidazole, DCM, rt, yield 95%; (b) triethyl 
phosphonoacetate, NaH, THF, 0 °C, yield 50%; (c) LiAlH4, THF, 
0 °C, yield 40%; (d) 9a-d, TEA or NMI, DCM, yields 36-56%; 
(e) TBAF, THF; (f) HCl, MeOH, yields 20-74%. B. Synthesis of 
aryl phosphorochloridates. Reagents and conditions: (g) Et2O, 
TEA, -78 °C, yields 54-95%. Me: methyl; iPr: isopropyl; tBu: tert-
butyl; Bn: benzyl. 
 compound 4 did now show any activation of Vγ9/Vδ2 T-cells 
(data not shown). 
Next, we tested the potential for ProPAgens to sensitise the 
urinary bladder carcinoma cell line T24 for targeted killing by 
in vitro expanded Vγ9/Vδ2 T cells. Without sensitization, me-
dium pulsed T24 cells were poorly targeted by increasing ratios 
of Vγ9/Vδ2 T cells, but upon pulsing for four hours with 
zoledronate or ProPAgens 5a-d, T24 cells were specifically 
lysed (Figure 3a). The short pulsing period, poor lipophilicity 
and requirement to target a metabolic enzyme resulted in only 
a marginal increase in specific T24 cell killing by zoledronate 
(Figure 3b). In contrast, a 1000-fold lower concentration of each 
ProPAgen mediated a 2-4-fold increase in specific lysis of T24 
over the same period (Figure 3b).   
The activity across the different HMBP ProPAgens in both 
biological assays was in agreement with what is typically ob-
served with aryloxy triester phosphoramidate (ProTide) pro-
drugs of nucleoside analogues as it correlated with the lipo-
philicity and rate of degradation. The HMBP ProPAgen with 
benzyl esters, e.g. 5b, has higher lipophilicity and thus better 
(passive) cellular uptake. Also, the benzyl group is better leav-
ing group than the other aliphatic esters and thus the metabolism 
of the benzyl ester of 5b proceeds faster than the other 
ProPAgens, 5a, 5c and 5d. Together, these explain the superior 
activity of ProPAgen 5b. HMBP ProPAgen 5a also exhibited 
relatively potent activation of Vγ9/Vδ2 T-cells with EC50 = 1.38 
nM. The fact that ProPAgen 5c, which has an isopropyl ester, 
exhibited lower potency in activating Vγ9/Vδ2 T-cells as com-
pared to 5a and 5d was surprising as often phosphoramidate 
prodrugs with this ester exhibit similar activity to those with a 
methyl ester. However, the less potent activity observed with 
the HMBP ProPAgen 5d was expected and is in agreement with 
the literature where phosphoramidate prodrugs with tBu esters 
show lower biological activity than those with other ester mo-
tifs. This is because the hydrolysis of the tBu ester group of the 
phosphoramidates by esterase enzymes proceeds much slower 
than those with Me, iPr and Bn esters. 
 
Figure 2. Activation of human Vγ9/Vδ2+ T cells by HMBP ProPAgens. (a) Human peripheral blood mononuclear cells (PBMC) 
were incubated with media or indicated concentrations of HMB-PP or Zoledronate for 18 h. TCR Vγ9/Vδ2+ T cells were then assessed 
for the upregulation of cell surface markers, CD69 and CD25. Data representative of n = 5. (b). As in (a), with PBMC incubated with 
indicated concentrations of HMBP ProPAgens. Data representative n = 4. (c). as in (a) and (b), with data showing titrations of each 
of HMB-PP, Zoledronate and HMBP ProPAgens, alongside a medium control (M). Data from n = 4-5 donors. (d) EC50, ED50 and 
selectivity index (SI) values for each HMBP ProPAgens. Specific cell death, for ED50 values, was calculated after adjusting for non-
specific cell death in medium controls. (e) CD69 and CD25 activation in CD3+ CD8+ αβ T-cells for each compound.  
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CONCLUSION 
We reported the application of the aryloxy triester phospho-
ramidate technology to the phosphoantigen HMBP and one of 
its synthetic analogues to generate HMBP ProPAgens. Alt-
hough the ProPAgens of the native HMBP compound (6a-d) 
were of very low stability, those of the synthetic analogue (5a-
d) were more stable. These later ones exhibited potent activa-
tion of Vγ9/Vδ2 T-cells. Notably, HMBP ProPAgen 5b was the 
most potent activator of Vγ9/Vδ2 T-cells, EC50 = 0.45 nM with 
the other three ProPAgens, 5a, c and d, also showing low nano-
molar activation. Impressively, Vγ9/Vδ2 T-cells activated by 
HMBP ProPAgens exhibited potent lysis of urinary bladder car-
cinoma cancer cells (T24) in vitro. In terms of specificity, 
HMBP ProPAgens, 5a-d, showed excellent specificity towards 
the activation of Vγ9/Vδ2 T-cells as they had no effects of other 
T-cells such as CD8+ αβ T-cells. Efforts aimed at improving 
the stability of the native HMBP ProPAgens are currently un-
derway and will be reported in the future. In conclusion, the ap-
plication of the aryloxy triester phosphoramidate prodrug tech-
nology to HMBP to generate HMBP ProPAgens yielded potent 
and specific activators of Vγ9/Vδ2 T-cells. Together, this show-
cases the promise of this prodrug technology in the discovery 
of novel immunotherapeutic agents. 
EXPERIMENTAL SECTION  
General Information. All of the reactions were carried out under 
argon atmosphere and were monitored with analytical thin layer 
chromatography (TLC). NMR data were recorded either on a 
Bruker AV300, AVIII300, AV400, AVIII400 or DRX500 spec-
trometers in the deuterated solvents indicated and the spectra were 
calibrated on residual solvent peaks. Chemical shifts (δ) are quoted 
in ppm and J values are quoted in Hz. In reporting spectral data, the 
following abbreviations were used: s (singlet), d (doublet), t (tri-
plet), q (quartet), dd (doublet of doublets), td (triplet of doublets) 
and m (multiplet). HPLC was carried out on a DIONEX summit 
P580 quaternary low-pressure gradient pump with a built-in vac-
uum degasser using a Summit UVD 170s UV/Vis multichannel de-
tector. HPLC grade solvents were used. Chromeleon software was 
used to visualize and process the obtained chromatograms. Analyt-
ical separations used a flow rate of 1 mL/min and preparative used 
a flow rate of 20 mL/min. The purity of the tested compounds was 
determined by high-performance liquid chromatography (HPLC) 
where all of the tested compounds had ³ 95% purity.  
1-((tert-butyldimethylsilyl)oxy)propan-2-one, 2. Hydroxyace-
tone 1 (1.00 g, 13.50 mmol, 1 eq.) and TBSCl (3.05 g, 20.25 mmol, 
1.5 eq.) were combined in dry CH2Cl2 (50 mL) under an argon. 
Imidazole (2.02 g, 29.70, 2.2 eq.) was then added portion-wise at 0 
°C. The mixture was allowed to warm to room temperature and left 
to stir at that temperature for 2.5 h. The reaction mixture was then 
washed with brine (50 mL), extracted with Et2O (50 mL x 3), dried 
(MgSO4) and the solvents removed under reduced pressure to give 
a crude oil, which was purified via column chromatography (10:1 
Hexane:EtOAc). 2 obtained as a colorless oil (2.45 g, 95%). δH 
NMR (300 MHz, CDCl3): 4.15 (s, 2H, CH2), 2.17 (s, 3H, CH3), 
0.93 (s, 9H, CH3), 0.09 (s, 6H, CH3). δC NMR (101 MHz, CDCl3): 
209.25, 69.57, 25.98, 25.76, 18.29, -5.51. MS-ESI (%): 211.1 (100, 
M+Na). 
Ethyl (E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-eno-
ate, 3. To a 0 °C suspension of NaH (0.20 g, 8.38 mmol, 1 eq.) in 
dry THF (50 mL) under an argon was added diethyl phosphonoace-
tate (1.88 g, 8.38 mmol, 1 eq.) dropwise. The resulting solution was 
left to stir for 25 min at 0 °C. Silyl ether 2 (1.5 g, 7.96 mmol, 0.95 
eq.) was then added dropwise as a solution in dry THF (25 mL). 
The mixture was then stirred at 0 °C for a further 30 min, then 
warmed to room temperature and stirred for a further 2 h, or until 
complete via TLC. A saturated solution of brine (50 mL) was 
added, dropwise at first, then the organic layer was extracted with 
Et2O (50 mL x 3), dried (MgSO4) and the solvents were removed 
to give a mixture of E:Z isomers (5:1 via 1H NMR) as a crude oil. 
This was purified via column chromatography (10% Et2O in Hex-
ane) to give product 3 as a colorless oil (1.04 g, 50%). δH NMR 
(300 MHz, CDCl3): 5.99 (d, J = 1.4 Hz, 1H, CH), 4.17 (q, J = 7.1 
Hz, 2H, CH2), 4.11 (d, J = 1.4 Hz, 2H, CH2), 2.05 (s (broad), 3H, 
CH3), 1.29 (t, J = 7.1 Hz, 3H, CH3), 0.93 (s, 9H, CH3), 0.09 (s, 6H, 
CH3). δC NMR (101 MHz, CDCl3): 167.10, 157.16, 113.35, 67.10, 
59.59, 25.88, 18.37, 15.44, 14.36, -5.45. MS-ESI (%): 258.2 (8, M), 
243.2 (100, M – CH3). 
(E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-en-1-ol, 4. 
In a flame dried Schleck flask were placed ester 3 (0.5 g, 1.93 
mmol, 1 eq.) and 20 mL dry THF, and the resulting mixture was 
cooled to 0 °C with stirring. Then LiAlH4 (1 M solution in THF) 
(1.93 mL, 1.93 mmol, 1 eq.) was added dropwise, and the solution 
was allowed to warm up to room temperature and stirred for 2 h. 
MeOH (1 mL) was then added cautiously, after which a saturated 
solution of sodium potassium tartrate (30 mL) was added which 
formed a white gel. This was stirred overnight at room temperature 
and then the phases were allowed to separate. The organic layer 
was collected and the aqueous layer was washed with Et2O (20 mL 
x 3), dried (MgSO4) and the solvents were removed under reduced 
pressure to leave a crude oil. This was then purified by column 
chromatography using hexane:ethyl acetate (4:1) as an eluant to 
give product 4 (0.1677 g, 40%) as a colorless oil. δH (300 MHz, 
CDCl3) 5.72-5.65 (m, 1H, CH), 4.21 (d, J = 6.9 Hz, 2H, CH2), 4.04 
(s, 2H, CH2), 1.65 (s (broad), 3H, CH3), 0.92 (s, 9H, 3 x CH3), 0.08 
(s, 6H, CH3). δC (101 MHz, CDCl3) 138.32, 122.53, 67.66, 59.14, 
25.94, 18.41, 13.50, -5.34. MS (ESI) (%): 239.1 (100, M+Na). 
Methyl ((((E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-
en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 5a. To a stirring 
solution of alcohol 4 (0.1301 g, 0.6166 mmol, 1 eq.) in dry CH2Cl2 
(10 mL) was added methyl phosphorochloridate 9a (0.2055 g, 
0.7400 mmol, 1.2 eq.). The solution was cooled to 0 °C and NMI 
(0.10 mL g, 1.2333 mmol, 2 eq.) was added dropwise and the re-
sulting solution was warmed to room temperature and stirred over-
night. Brine (10 mL) was then added and the organic layer sepa-
rated off. The aqueous layer was then extracted with Et2O (20 mL 
x 3), the organic layers combined, dried (MgSO4) and the solvents 
removed under reduced pressure to leave a crude oil. This was then 
Figure 3. HMBP ProPAgens mediate the specific lysis of 
bladder cancer cells by Vγ9/Vδ2 T-cells. (a) Human T24 uri-
nary bladder carcinoma cell lines (Target) were pulsed for 4 hours 
with 10 nM of the indicated ProPAgens, media or Zoledronate, then 
co-cultured for 18 hours with expanded Vγ9/Vδ2 T cells (Effector) 
at the indicated Target:Effector ratios. Specific killing of target 
cells was measured by an amine-reactive dead cell marker staining. 
Data display the mean of n = 2. (b). As in (a) showing the mean ± 
SD specific killing of T24 cells at 1:10 Target:Effector ratio for 
each indicated treatments, n = 2. * P < 0.05; ** P < 0.01; deter-
mined by One-way ANOVA. 
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 purified by column chromatography (4:1 Hex:EtOAc to 1:1 
Hex:EtOAc) to give compound 5a (0.1228 g, 43%) as a colourless 
oil. δH NMR (400 MHz, CDCl3): 7.31 (t, J = 7.3 Hz, 2H, 2 x CH), 
7.21 (t, J = 7.3 Hz, 2H, 2 x CH), 7.14 (t, J = 7.3 Hz, 1H, CH), 5.75-
5.59 (m, 1H, CH), 4.72-4.64 (m, 2H, CH2), 4.10-3.97 (m, 3H, CH2 
& CH), 3.70 (d, J = 8.8 Hz, 3H, CH3), 3.53 (dd, J = 18.0, 9.7 Hz, 
1H, NH), 1.65 (d, J = 3.5 Hz, 3H, CH3), 1.37 (t, J = 7.4 Hz, 3H, 
CH3), 0.91 (s, 9H, 3 x CH3), 0.07 (s, 6H, 2 x CH3). δC NMR (101 
MHz, CDCl3): 173.96 (d, J = 6.0 Hz), 150.89 (d, J = 5.7 Hz,), 
141.03, 129.58, 124.70, 120.22, 117.86 (d, J = 7.1 Hz), 67.28, 
63.28 (t, J = 5.0 Hz), 52.43, 50.11 (d, J = 4.1 Hz), 25.90, 21.05 (d, 
J = 3.3 Hz), 18.37, 13.59, -5.39. δP NMR (121 MHz, CDCl3) 2.48, 
2.50. HRMS (ESI): Found M+Na, 480.1949, [C21H36NO6SiPNa] 
requires 480.1947. 
Benzyl ((((E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-
en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 5b. Prepared 
under the same procedure as described for 5a using alcohol 4 (0.16 
g, 0.77 mmol, 1 eq.), benzyl phosphorchloridate 9b (0.32 g, 0.92 
mmol, 1.2 eq.) and dry Et3N (0.22 mL, 1.5496 mmol, 2 eq.) to give 
a crude yellow oil which was then purified by column chromatog-
raphy (4:1 Hex:EtOAc to 2:3 Hex:EtOAc) to afford 5b (0.1306 g, 
31%) as a colourless oil. δH NMR (400 MHz, CDCl3) δ 7.44 – 7.06 
(m, 10H, Ph), 5.66 (m, 1H, CH), 5.18-5.09 (m, 2H, CH2), 4.71-4.61 
(m, 2H, CH2), 4.13-4.04 (m, 1H, CH), 4.02 (d, J = 5.3 Hz, 2H, 
CH2), 3.59-3.45 (m, 1H, NH), 1.63 (d, J = 5.1 Hz, 3H, CH3), 1.38 
(t, J = 6.9 Hz, 3H, CH3), 0.91 (s, 9H, CH3), 0.06 (s, 6H, 2 x CH3). 
δC NMR (101 MHz, CDCl3): 173.32 (2 x s), 150.88 (s), 141.06 (2 
x s), 135.28, 129.59 (2 x s), 128.64 (2 x s), 128.48 (2 x s), 128.19 
(2 x s), 124.71 (2 x s), 120.23 (s (broad)), 117.87 (2 x s), 67.32 (2 
x s (broad)), 67.18 (2 x s (broad)), 63.35 (2 x s), 50.25 (2 x s), 25.91 
(2 x s), 21.11 (2 x s), 13.59 (2 x s), -5.37. δP NMR (121 MHz, 
CDCl3): 2.38, 2.56. HRMS (ESI): Found M+Na, 556.2262, 
[C27H40NO6PSiNa] requires 556.2260. 
Isopropyl ((((E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-
2-en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 5c. Prepared 
under the same procedure as described for 5a using alcohol 4 (0.23 
g, 1.08 mmol, 1 eq.), isopropyl phosphorchloridate 9c (0.39 g, 1.29 
mmol, 1.2 eq.) and dry Et3N (0.30 mL, 2.16 mmol, 2 eq.) to give a 
crude yellow oil which was then purified by column chromatog-
raphy (4:1 Hex:EtOAc) to afford 5c (0.1914 g, 36%) as a colorless 
oil. δH NMR (400 MHz, CDCl3) 7.30 (td, J = 8.5, 2.1 Hz, 2H, 2 x 
CH), 7.20 (td, J = 7.5, 0.9 Hz, 2H, 2 x CH), 7.16-7.08 (m, 1H, CH), 
5.66 (q, J = 7.2 Hz, 1H, CH), 5.06-4.92 (m, 1H, CH), 4.75-4.59 (m, 
2H, CH2), 4.02 (s, 2H, CH2), 4.00-3.88 (m, 1H, CH), 3.60-3.48 (m, 
1H, NH), 1.63 (s, 3H, CH3), 1.38-1.32 (m, 3H, CH3), 1.26-1.17 (m, 
6H, 2 x CH3), 0.90 (s, 9H, 3 x CH3), 0.05 (s, J = 4.2 Hz, 6H, 2 x 
CH3). δC NMR (101 MHz, CDCl3) 173.00 (2 x d, J = 4.13 Hz), 
150.92 (t, J = 6.7 Hz), 140.96, 129.57, 124.68 (s (broad)), 120.23 
(t, J = 4.6 Hz), 117.92 (2 x s), 69.11, 67.30, 63.28 (t, J = 5.1 Hz), 
50.30 (2 x s), 25.90, 21.66 (2 x s), 21.09 (2 x s), 18.37, 13.59, -5.39. 
δP NMR (121 MHz, CDCl3): 2.62, 2.65. HRMS (ESI): Found 
M+Na, 508.2258, [C23H40NO6PSiNa] requires 508.2260. 
Tert-butyl ((((E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-
2-en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 5d. Prepared 
under the same procedure as described for 5a using alcohol 4 (0.14 
g, 0.65 mmol, 1 eq.), tert-butyl phosphorchloridate 9d (0.25 g, 0.78 
mmol, 1.2 eq.) and dry NMI (0.11 mL, 1.30 mmol, 2 eq.) to give a 
crude yellow oil which was then purified by column chromatog-
raphy (4:1 Hex:EtOAc) to afford 5d (0.1832 g, 56%) as a colorless 
oil. δH NMR (400 MHz, CDCl3): 7.29 (t, J = 7.2 Hz, 2H, 2 x CH), 
7.22 (t, J = 7.2, 2H, 2 x CH), 7.12 (t, J = 7.2 Hz, 1H, CH), 5.68 (qd, 
J = 7.2, 1.3 Hz, 1H, CH), 4.74-4.62 (m, 2H, CH2), 4.02 (s, 2H, 
CH2), 3.95-3.83 (m, 1H, CH), 3.73-3.62 (m, 1H, NH), 1.64 (s, 3H, 
CH3), 1.43 (2 x s, 9H, 3 x CH3), 1.33 (2 x d, J = 3.1 Hz, 3H, CH3), 
0.91 (s, 9H, 3 x CH3), 0.07 (s, 6H, 2 x CH3). δC NMR (101 MHz, 
CDCl3): 172.64 (2 x d, J = 4.1 Hz), 150.94 (t, J = 6.2 Hz), 140.76, 
129.49, 124.55, 120.21 (t, J = 4.8 Hz), 118.01 (2 x s (broad)), 81.69, 
67.27, 63.15 (t, J = 5.0 Hz), 50.66 (2 x s), 27.86, 25.87, 21.06 (2 x 
s), 18.31, 13.53, -5.41. δP NMR (121 MHz, CDCl3): 2.82 (s 
(broad)). HRMS (ESI): Found M+Na, 522.2415, 
[C24H42NO6SiPNa] requires 522.2417. 
Methyl ((((E)-4-hydroxy-3-methylbut-2-en-1-yl)oxy)(phe-
noxy)phosphoryl)-L-alaninate, 6a. The silyl ether 5a (0.12 g, 0.26 
mmol, 1 eq.) was placed in a flask containing MeOH (3 mL). HCl 
(1.25 M in MeOH, 0.0215 mL, 0.0268 mmol, 0.1 eq.) was then 
added at 0 °C and the resulting solution was warmed to room tem-
perature while stirring for 40 min, until complete via TLC, upon 
which it was neutralized with sodium bicarbonate. The mixture was 
then filtered, and MeOH removed under reduced pressure. Brine 
(10 mL) and CH2Cl2 (10 mL) were then added. The organic layer 
was collected and the aqueous layer was extracted with CH2Cl2 (10 
mL x 3). The organic layers were combined, dried (MgSO4) and 
the solvents removed under reduced pressure to leave a crude 
brown oil. This was then purified by column chromatography (4:1 
Hex:EtOAc) to leave 6a (0.0920 g, 49%) as a colorless oil.  δH 
NMR (400 MHz, CDCl3): 7.32 (t, J = 7.8 Hz, 2H, 2 x CH), 7.25-
7.18 (m, 2H, 2 x CH), 7.15 (t, J = 7.3 Hz, 1H, CH), 5.67 (dtd, J = 
12.5, 7.0, 1.4 Hz, 1H, CH), 4.78-4.58 (m, 2H, CH2), 4.16-3.93 (m, 
3H, CH2 & CH), 3.71 (d, J = 8.4 Hz, 3H, CH3), 3.64-3.43 (m, 1H, 
NH), 1.70 (s, 3H, CH3), 1.37 (t, J = 7.0 Hz, 3H, CH3). δC NMR 
(101 MHz, CDCl3): 174.11 (2 x s), 150.78 (2 x s), 141.65 (s 
(broad)), 129.60, 124.76, 120.19 (t, J = 5.5 Hz), 118.48 (t, J = 7.2 
Hz), 67.19, 63.49 (t, J = 5.7 Hz), 52.47 (s), 50.14 (2 x s), 20.95 (t, 
J = 5.3 Hz), 13.78. δP NMR (121 MHz, CDCl3): 2.42, 2.57. HRMS 
(ESI): Found M+Na, 366.1081, [C15H22NO6PNa] requires 
366.1082. 
Benzyl ((((E)-4-hydroxy-3-methylbut-2-en-1-yl)oxy)(phe-
noxy)phosphoryl)-L-alaninate, 6b. Prepared following the same 
procedure as described for 6a using silyl ether 5b (0.13 g, 0.24 
mmol, 1 eq.) and HCl (1.25 M in MeOH, 0.19 mL, 0.24 mmol, 1 
eq.) in dry MeOH (5 mL), to give a crude brown oil after 2 h. This 
was then purified by column chromatography (1:1 Hex:EtOAc to 
1:4 Hex:EtOAc) to afford 6b (0.0207 g, 20%) as a colorless oil. δH 
NMR (400 MHz, CDCl3): 7.53-7.02 (m, 10H, Ph), 5.64 (dtd, J = 
21.5, 7.0, 1.3 Hz, 1H, CH), 5.13 (d, J = 11.7 Hz, 2H, CH2), 4.75-
4.57 (m, 2H, CH2), 4.15-4.01 (m, 1H, CH), 3.99 (d, J = 8.9 Hz, 2H, 
CH2), 3.65-3.50 (m, 1H, NH), 1.97 (s (broad), 1H, OH), 1.68 (d, J 
= 4.8 Hz, 3H, CH3), 1.37 (t, J = 7.0 Hz, 3H, CH3). δC NMR (100 
MHz, CDCl3): 173.45 (2 x d, J = 3.3 Hz), 150.82 (t, J = 6.1 Hz), 
141.44 (s (broad)), 135.23, 129.60, 128.65, 128.51 (2 x s), 128.20, 
124.78, 120.23 (2 x d, J = 5.0 Hz), 118.81 (2 x d, J = 6.5 Hz), 67.43, 
67.24, 63.40 (t, J = 5.8 Hz), 50.29 (2 x s), 29.70, 13.81. δP NMR 
(121 MHz, CDCl3):  2.36, 2.53. HRMS (ESI): Found M+Na, 
442.1392, [C21H26NO6PNa] requires 442.1395. 
Isopropyl ((((E)-4-hydroxy-3-methylbut-2-en-1-yl)oxy)(phe-
noxy)phosphoryl)-L-alaninate, 6c. Prepared following the same 
procedure as described for 6a using silyl ether 5c (0.19 g, 0.39 
mmol, 1 eq.) and HCl (1.25 M in MeOH, 0.03 mL, 0.0364 mmol, 
0.1 eq.) in dry MeOH (5 mL), to give a crude brown oil after 1.5 h. 
This was then purified by column chromatography (1:1 
Hex:EtOAc) to afford 6c (0.0725 g, 49%) as a colorless oil. δH 
NMR (400 MHz, CDCl3): 7.34-7.28 (m, 2H, CH), 7.21 (t, J = 7.4 
Hz, 2H, 2 x CH), 7.14 (t, J = 7.3 Hz, 1H, CH), 5.73-5.61 (m, 1H, 
CH), 5.08-4.91 (m, 1H, CH), 4.76-4.57 (m, 2H, CH2), 4.04 – 3.86 
(m, 3H, CH2 & CH), 3.77-3.64 (m, 1H, NH), 2.89 (s, 1H, OH), 1.68 
(s, 3H, CH3), 1.34 (t, J = 6.5 Hz, 3H, CH3), 1.22 (ddd, J = 11.7, 7.0, 
5.5 Hz, 6H, 2 x CH3). δC NMR (101 MHz, CDCl3): 173.21 (2 x s), 
150.90 (t, J = 6.2 Hz), 141.69 (s, (broad)), 129.66, 124.81, 120.28 
(2 x d, J = 4.8 Hz), 118.63 (t, J = 5.7 Hz), 69.28, 67.26, 63.52 (t, J 
= 5.1 Hz), 50.37 (2 x s), 21.71 (2 x s), 21.19-20.94 (m), 13.85. δP 
NMR (121 MHz, CDCl3): 2.54, 2.68. 
Tert-butyl ((((E)-4-hydroxy-3-methylbut-2-en-1-yl)oxy)(phe-
noxy)phosphoryl)-L-alaninate, 6d. Prepared following the same 
procedure as described for 6a using silyl ether 5d (0.1832 g, 0.3666 
 mmol, 1 eq.) and HCl (1.25 M in MeOH, 0.0293 mL, 0.0366 mmol, 
0.1 eq.) in dry MeOH (3 mL), to give a crude brown oil. This was 
then purified by column chromatography (2:3 Hex:EtOAc) to af-
ford 6d (0.0983 g, 74%) as a colourless oil. δH NMR (400 MHz, 
CDCl3): 7.31 (t, J = 7.2 Hz, 2H,  2 x CH), 7.21 (dd, J = 7.6, 6.6 Hz, 
2H, 2 x CH), 7.13 (t, J = 7.3 Hz, 1H, CH), 5.73-5.61 (m, 1H, CH), 
4.75-4.59 (m, 2H, CH2), 3.99 (s (broad), 2H, CH2), 3.96-3.80 (m, 
1H, CH), 3.72-3.61 (m, 1H, NH), 2.96 (s (broad), 1H, OH), 1.68 (s, 
3H, CH3), 1.43 (2 x s, 9H, CH3), 1.36-1.29 (t, J = 6.3 Hz, 3H, CH3). 
δC NMR (101 MHz, CDCl3): 172.79 (2 x s), 150.86 (t, J = 6.1 Hz), 
141.57, 129.58, 124.69, 120.22 (2 x d, J = 4.9 Hz), 118.61 (2 x s), 
81.97, 67.19, 63.40 (t, J = 5.1 Hz), 50.70, 27.89, 21.11 (2 x d, J = 
4.6 Hz), 13.79. δP NMR (121 MHz, CDCl3): 2.70, 2.79. HRMS 
(ESI): Found M+Na, 408.1554, [C18H28NO6PNa] requires 
408.1554.  
Methyl (chloro(phenoxy)phosphoryl)-L-alaninate, 9a. Phenyl 
phosphorodichloridate 7 (0.2 g, 0.95 mmol, 1 eq.) and L-alanine 
methyl ester hydrogen chloride (0.13 g, 0.95 mmol, 1 eq.) were 
combined in dry CH2CL2 (10 mL) under an argon flow at -78 °C, 
and stirred at -78 °C for 20 minutes. Dry Et3N (0.26 mL, 1.90 
mmol, 2 eq.) was then added dropwise over 15 minutes and the 
reaction stirred at -78 °C for a further 30 minutes. The temperature 
is then raised to room temperature and the reaction stirred for a fur-
ther 3.5 hours. The solvents are removed under reduced pressure, 
and the mixture is filtered and washed with Et2O, which is removed 
under reduced pressure to give a crude oil. This is then purified by 
column chromatography (7:3 Hex:EtOAc) to give 9a as a colorless 
oil (0.14 g, 54%), which is stored under argon. δH NMR (300 MHz, 
CDCl3): 7.40-7.34 (m, 2H, 2 x CH), 7.29-7.23 (m, 3H, 2 x CH), 
4.66-4.49 (m, 1H, NH), 4.28-4.12 (m, 1H, CH), 3.78 (2 x s, 3H, 
CH3), 1.51 (2 x dd, J = 4.1, 0.5 Hz, 3H, CH3). δC (101 MHz, 
CDCl3): 173.11 (2 x d, J = 8.8 Hz), 149.73 (2 x d, J = 7.14 Hz), 
129.90, 125.99, 120.54 (2 x d, J = 1.4 Hz), 52.80 (2 x s), 50.39 (2 
x d, J = 1.5 Hz), 20.51 (2 x d, J = 1.5 Hz). δP NMR (121 MHz, 
CDCl3): 7.62, 7.94.  
Benzyl (chloro(phenoxy)phosphoryl)-L-alaninate, 9b. Followed 
same procedure as described for 9a using 7 (0.35 mL, 3.32 mmol, 
1 eq.), Et3N (0.63 mL, 4.64 mmol, 2 eq.) and L-alanine benzyl ester 
hydrogen chloride (0.5 g, 2.32 mmol, 1 eq.) to give phos-
phorchloridate 9b (0.505 g, 95%). δH NMR (300 MHz, CDCl3): 
7.42-7.32 (m, 7H, Ph), 7.25-7.20 (m, 3H, Ph), 5.21 (2 x s, 2H, 
CH2), 4.34-4.15 (m, 2H, CH & N-H), 1.52 (dd, J = 6.6, 2.4 Hz, 3H, 
CH3). δC NMR (101 MHz, CDCl3): 172.52 (dd, J = 11.6, 8.7 Hz), 
149.75 (dd, J = 11.6. 8.7 Hz), 135.05 (d, J = 5.8 Hz, C-10), 129.92, 
128.68, 128.59, 128.33, 125.99, 120.57, 67.60, 50.67, 20.47 (t, J = 
4.5 Hz). δP NMR (121 MHz, CDCl3): 7.49, 7.85. 
Isopropyl (chloro(phenoxy)phosphoryl)-L-alaninate, 9c. Fol-
lowed same procedure as described for 9a using 7 (0.62 mL, 4.18 
mmol, 1 eqvs), Et3N (1.13 mL, 8.36 mmol, 2 eqvs) and L-alanine 
isopropyl ester hydrogen chloride (0.700 g, 4.18 mmol, 1 eqvs) to 
give phosphorchloridate 9c (1.185 g, 93%). δH NMR (300 MHz, 
CDCl3): 7.41- 7.34 (m, 2H, 2 x CH), 7.30- 7.21 (m, 3H, 3 x CH), 
5.15-5.01 (m, 1H, CH), 4.50-4.31 (m, 1H, NH), 4.22-4.04 (m, 1H, 
CH), 1.50 (dd, J = 7.0, 2.1 Hz, 3H, CH3), 1.34-1.22 (m, 6H, 2 x 
CH3).  δC NMR (101 MHz, CDCl3): 172.15 (dd, J = 13.9, 9.2 Hz), 
149.76 (t, J = 7.0 Hz), 129.93, 125.98, 120.56 (d, J = 4.9 Hz), 69.79 
(d, J = 10.5 Hz), 50.70 (2 x s), 21.67 (2 x s), 20.55 (d, J = 4.4 Hz). 
δP NMR (121 MHz, CDCl3): 7.76, 8.11. 
tert-butyl (chloro(phenoxy)phosphoryl)-L-alaninate, 9d. Fol-
lowed same procedure as described for 9a using 7 (0.22 mL, 1.5 
mmol, 1 eq.), Et3N (0.42 mL, 3 mmol, 2 eq.) and L-alanine tert-
butyl ester hydrogen chloride (0.27 g, 1.5 mmol, 1 eq.) to give 
phosphorchloridate 9d (0.44 g, 90%). δH NMR (400 MHz, CDCl3): 
7.37 (t, J = 7.8 Hz, 2H, 2 x CH), 7.30-7.22 (m, 3H, 2 x CH), 4.46-
4.24 (m, 1H, NH), 4.16-3.97 (m, 1H, CH), 1.50-1.46 (m, 12H, 4 x 
CH3). δC NMR (101 MHz, CDCl3): 171.77 (dd, J = 15.8, 9.4 Hz), 
149.80, 129.92, 125.96, 120.57 (d, J = 5.0 Hz), 82.70 (2 x s), 51.09 
(2 x s), 27.93, 20.63. δP NMR (121 MHz, CDCl3): 7.85, 8.24. 
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I. T-cell isolation, culture and activation  
PBMCs were isolated from heparinised venous blood from consented healthy donors (approved by the NRES 
Committee West Midlands ethical board; REC reference 14/WM/1254). Blood was layered over lymphoprep© 
(Stem Cell Technologies) and PBMC isolated according to manufacturers instructions. The cell culture medium 
used throughout was RPMI-1640 media supplemented with 2 mM L-glutamine, 25 mM HEPES, 1% sodium py-
ruvate, 50 μg/ml penicillin/streptomycin (Invitrogen) and 10% fetal calf serum (Sigma). For activation assays, 5 x 
105 PBMC were cultured for 20 h in the presence of medium alone or the indicated concentrations of HMB-PP 
(Sigma), Zoledronate (Sigma), 5a, 5b, 5c and 5d (as described above). Cultured PBMC were labelled with Zombie© 
aqua viability dye (Biolegend) and cells were stained for surface antigens by antibodies directed against CD3 
(UCHT1; 1:100), CD8 (SK1; 1:200), CD25 (2A3; 1:200); all Biolegend, CD69 (TP1.55.3; 1:20) and TCR Vγ9 (IMMU360; 
1:400); Beckman Coulter, and TCR Vδ2 (123R3; 1:200); Miltenyi. For killing assays, Vγ9/Vδ2 T cells were expanded 
from 2 x 105/ml PBMC cultured with 10 μM zoledronate for 14 days and supplemented with 100 U/ml IL-2 into 
the media every 2-3 days, yielding 83 – 91% Vγ9/Vδ2 T cells. T24 (ATCC HTB4) cell line were labelled with 0.1μM 
CFSE and incubated for 4 hours with 10 μM zoledronate or 10 nM ProPAgens (5a - d), before being washed five-
times in medium and co-cultured with expanded Vγ9/Vδ2 T cells for 18 hours. All cells were then labelled with 
Zombie© aqua viability dye and CFSE+ Zombie© aqua+ cells measured. All data were acquired on an LSR II (Beckton 
Dickinson) and data analysed with FlowJo V10.1 (TreeStar). Tabulated data were analysed in Graphpad PRISM 7 
(Graphpad Software Inc). 
 
 
 
 
 
 
 
 Supporting Figure S1. 
 
 
Figure S1: 31P NMR of HMBP ProPAgen 6d incubated with the carboxypeptisade cathepsin A. The two singlets at 4.02 ppm 
corresponds to the two diastereoisomers of ProPAgen 6d. The singlet at 6.87 ppm corresponds to the amino acyl monoester as shown. 
The singlet at 1.98 ppm corresponds to the degradation product shown in the figure and confirmed by mass spec (see below). The 
presence of the undesired metabolite that has a 31P NMR is a reflection of the low stability of these compounds. The experiment was 
carried out as reported previously by Osgerby et al. 2017, 60 (8), 3518–3524. 
 
 
Figure S2. Negative ion spectrum for HMBP ProPAgen 6d following incubation with cathepsin A for 72 hours. 
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 II. NMR spectra 
1-((tert-butyldimethylsilyl)oxy)propan-2-one, 2: 
1H NMR 
 
13C NMR 
 
 Ethyl (E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-enoate, 3: 
1H NMR 
 
13C NMR 
 
 (E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-en-1-ol, 4: 
1H NMR 
 
13C NMR 
 
 Methyl (chloro(phenoxy)phosphoryl)-L-alaninate, 9a: 
1H NMR 
 
13C NMR 
 
 31P NMR 
 
Benzyl (chloro(phenoxy)phosphoryl)-L-alaninate, 9b: 
1H NMR 
 
 13C NMR 
 
31P NMR 
 
 Isopropyl (chloro(phenoxy)phosphoryl)-L-alaninate, 9c: 
1H NMR 
 
13C NMR 
 
 31P NMR 
 
Tert-butyl (chloro(phenoxy)phosphoryl)-L-alaninate, 9d: 
1H NMR 
 
 13C NMR 
 
31P NMR 
 
 
 Methyl ((((E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-en-1-yl)oxy)(phenoxy)phos-
phoryl)-L-alaninate, 5a: 
1H NMR 
 
13C NMR 
 
 1H COSY 
 
13C DEPT-45 
 
 HSQC 
 
31P NMR 
 
Benzyl ((((E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-en-1-yl)oxy)(phenoxy)phos-
phoryl)-L-alaninate, 5b: 
 1H NMR 
 
13C NMR 
 
 1H COSY 
 
13C DEPT-45 
 
 HSQC 
 
31P NMR 
 
 Isopropyl ((((E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-en-1-yl)oxy)(phe-
noxy)phosphoryl)-L-alaninate, 5c: 
1H NMR 
 
13C NMR 
 
 1H COSY 
 
13C DEPT-45 
 
 HSQC 
 
31P NMR 
 
 
 Tert-butyl ((((E)-4-((tert-butyldimethylsilyl)oxy)-3-methylbut-2-en-1-yl)oxy)(phe-
noxy)phosphoryl)-L-alaninate, 5d: 
1H NMR 
 
13C NMR 
 
 1H COSY 
 
13C DEPT-45 
 
 HSQC 
 
31P NMR 
 
 
Methyl ((((E)-4-hydroxy-3-methylbut-2-en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 6a: 
 1H NMR 
 
13C NMR 
 
1H COSY 
  
`13C DEPT-45 
 
HSQC 
  
31P NMR 
 
 
Benzyl ((((E)-4-hydroxy-3-methylbut-2-en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 6b: 
 1H NMR 
 
13C NMR 
 
1H COSY 
  
13C DEPT-45 
 
HSQC 
  
31P NMR 
 
Isopropyl ((((E)-4-hydroxy-3-methylbut-2-en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 
6c: 
1H NMR 
  
13C NMR 
 
1H COSY 
  
13C DEPT-45 
 
HSQC 
  
31P NMR 
 
 
 Tert-butyl ((((E)-4-hydroxy-3-methylbut-2-en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 
6d: 
1H NMR 
 
13C NMR 
 
 1H COSY 
 
13C DEPT-45 
 
 HSQC 
 
31P NMR 
 
 
 III. HPLC spectra 
 
 
 
 
 
 
Compound 5a 
  
 
 
 
 
 
 
Compound 5b 
  
 
 
 
 
 
 
Compound 5c 
  
 
 
 
 
 
 
Compound 5d 
 IV. Mass spec data 
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Compound 5c 
Compound 5d 
